Stocks · News reference
Envoy Medical Submits Second FDA Module Of Its PMA Application For The Acclaim Cochlear Implant; Targets Final Clinical Submission In Q2 2027
Second of Four Planned Modules Moves Rolling FDA Review ForwardAdvances Toward Targeted Completion of the Final Clinical Module Submission in Q2 2027White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) -
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lake Street Initiates Coverage On Envoy Medical with Buy Rating, Announces Price Target of $2.5
Lake Street analyst Frank Takkinen initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $2.5.
Envoy Medical Granted Two Additional Global Patents Over Its IP Portfolio
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international